Russian media reported today that experts from the European Medicines Agency (EMA) are evaluating a vaccine against covida-19 Sputnik V in Moscow.
Representatives of the European regulatory agency headquartered in Amsterdam launched the Russian vaccine analysis program in early March. To date, they have visited two clinics in Moscow, and patients are seen in the key Phase III clinical trial.
According to Interfax news agency, EMA experts talked with medical staff in two clinics, citing unnamed sources.
The agency added that it also plans to produce factory reports.
The visit of EMA experts to Russia is part of the analysis and evaluation process of the effectiveness of the Sputnik V vaccine.
The program analyzed the results of clinical trials, although not all data was available, and no approval request was submitted.
At present, it is not clear how long the entire process will take.
Although EMA has not yet obtained approval for Sputnik V, Hungary has approved the vaccine through a shorter process, and some EU countries have expressed interest in reaching an agreement with Russia to purchase the vaccine.